KIKA Clinical Solutions reports 47% increase in service bookings during first-half of 2010

KIKA™ Clinical Solutions is on track for unprecedented 2010 growth. KIKA is the leading provider of advanced EDC solutions for Clinical Asset Management™ for the pharmaceutical, biotechnology and medical device markets.

“Sponsors are migrating to Veracity™ because it is the most reliable, flexible, innovative EDC platform on the market. With Veracity™ sponsors are confident that they can collect, protect, control and maximize their most important clinical trial asset - their data.”

For the first half of this year service bookings soared 47% over the same period in 2009, with a strong revenue pipeline from direct sales, joint sales with partners, and technology transfers.

KIKA has won 30 new trials from new and existing customers in therapeutic areas including electrophysiology, interventional cardiology, cardiovascular; interventional radiology; neuroradiology; oncology; orthopedics; thoracic/vascular surgery; and, urology. 67 % of bookings were generated from existing customers who are increasing the use of KIKA's Veracity™ advanced EDC platform on more clinical trials.

KIKA CEO Linda Beneze said, "Sponsors are migrating to Veracity™ because it is the most reliable, flexible, innovative EDC platform on the market. With Veracity™ sponsors are confident that they can collect, protect, control and maximize their most important clinical trial asset - their data."

Additional 20010 KIKA highlights included:

Veracity™ 3.9 - KIKA announced a significant Veracity™ upgrade at the 46th DIA Annual Meeting. Veracity™ is a highly configurable, collaborative platform for all clinical trial stakeholders. Veracity's™ Web services architecture makes it open and ready to integrate with a customer's clinical IT and CTMS systems. Veracity™ 3.9 features include enhanced signature and manual queries workflow; form completeness management; new filtering options for export; notification improvements; an improved user experience; and, additional operating systems support. Veracity™ is part of KIKA's exclusive three-part approach to clinical trial management, along with Clinical Asset Management and ISO-certified Professional Services.

KIKA 2nd Annual European User Group Meeting - KIKA gathered customers and partners at its second annual KIKA European User Group Meeting in Chantilly, France last May. The agenda provided a mix of presentations, breakout sessions and panels that offered attendees information and insights on the use of KIKA's groundbreaking EDC solutions.

Industry Leadership - KIKA and Accuray Incorporated conducted an important Webinar entitled, "The Next Generation of EDC." Attendees learned how one company protects their clinical assets with KIKA's advanced EDC solutions. Discussion included how making the monitoring function more efficient improves the quality of the site visit; how the reporting tools in Veracity™ make it easier to see the status of a trial from multiple perspectives; and how to attach images to the CRF to boost the value of its contents.

Thought Leadership - KIKA and Quintiles co-authored an article entitled, "Electronic Endpoint Adjudication; How an Integrated, EDC-based System Can Optimize the Endpoint Process" which was published in Applied Clinical Trials Magazine.

Technology Partnerships - KIKA announced a partnership with Danish CRO BioStata ApS to provide Veracity™ for clinical trial management and their unique

Endpoint Adjudication System. BioStata ApS specializes in statistics and worldwide Endpoint Adjudication Committee and DMC/DSMB services. KIKA also announced that Carestream Health, Inc, will work with KIKA to perform a knowledge transfer for use of KIKA's technology on six global clinical trials that require electronic data capture this year.

Source KIKA Clinical Solutions

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AHN Biotechnologie GmbH – Premium private label manufacturing biotechnology